Clinical trials: Rivaroxaban
Pulmonary Embolism
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs.
- Trial name
- XAPEC (NCT03410706)
- Testing
- Rivaroxaban(Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Bayer
Rivaroxaban, Thromboprophylaxis
Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
Rivaroxaban has been developed in the various clinical settings.Although cancer-associated DVT or PE was included in previously programs, limited patients of the total populations were cancer patients with totally implantable…
- Conditions
- Rivaroxaban, Thromboprophylaxis, Cancer
- Trial name
- NCT04309240
- Testing
- Rivaroxaban
- Volunteers
- 204 people
- Sponsor
- LiuZhou People's Hospital
COVID-19
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
- Trial name
- NCT04504032
- Testing
- Rivaroxaban
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 497 people
- Sponsor
- Gates Medical Research Institute
Anticoagulants; Increased
Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
Direct Oral Anticoagulants INTRODUCTION: DOAC's looks like an attractive alternative to VKA because they offer important advantages beyond their easiness of administration, like less interactions and no need of laboratory…
- Trial name
- NCT05705076
- Testing
- catheter induced thromboprophylaxis
- Volunteers
- 1,100 people
- Sponsor
- Mansoura University
Atrial Fibrillation, Venous Thromboembolism
Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm
This study shall determine whether XAPPORT - a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice - provides adequate guidance to physicians…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- VeriXAPPORT (NCT02900404)
- Testing
- XAPPORT, Expert Panel ("gold standard")
- Sponsor
- Bayer
Thrombosis, Bleeding
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients .
- Conditions
- Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure
- Trial name
- NCT07358416
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Atrial Fibrillation New Onset
Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery
Coronary artery bypass graft (CABG) surgery is a common intervention in patients with coronary artery disease (CAD). The presence of new postoperative atrial fibrillation / atrial flutter (POAF) occurs in 15-40% of patients…
- Trial name
- TASK-POAF (NCT05300555)
- Testing
- Rivaroxaban 20 MG Oral Tablet, Warfarin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo General Hospital
Atrial Fibrillation
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of…
- Trial name
- NCT04297150
- Testing
- Apixaban, Edoxaban, Rivaroxaban
- Where
- 6 sites in Spain
- Volunteers
- 700 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Stroke
Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study
This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.
- Trial name
- XASSURE (NCT02784717)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 3,055 people
- Sponsor
- Bayer
Healthy
A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
The purpose of this study is to explore the pharmacodynamic (what the drug does to the body) changes when transitioning from rivaroxaban 20 mg once daily to warfarin dosed to a therapeutic level as measured by the International…
- Trial name
- NCT01400646
- Testing
- Rivaroxaban, Warfarin, Vitamin K
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients.
- Conditions
- Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
- Trial name
- NCT02502396
- Testing
- Retrospective Chart Review
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Atrial Fibrillation, Cardioversion
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between…
- Conditions
- Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke
- Trial name
- AFTER-CV (NCT01924065)
- Testing
- Cardioversion, Oral Anticoagulant
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Suleyman Demirel University
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Treatment of Venous Thromboembolism
A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database
This is an observational study in which data from the past is collected for a treatment which is already available for doctors to prescribe for venous thromboembolism (VTE).
- Trial name
- NCT04923139
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in Japan
- Volunteers
- 2,627 people
- Sponsor
- Bayer
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Ventricular Mural Thrombosis
An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
To study the effect of rivaroxaban anticoagulant therapy for 12 weeks in patients with left ventricular mural thrombus by contrast echocardiography before and after treatment, so as to provide basis and foundation for further…
- Trial name
- R-DISSOLVE (NCT04970381)
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 75 people
- Sponsor
- China National Center for Cardiovascular Diseases
Atrial Fibrillation
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial…
- Trial name
- NCT00973245
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Warfarin
- Where
- 11 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Acute Myocardial Infarction
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina
- Trial name
- NCT03481257
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital